Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab

Giovanni Rossi, Matteo Bauckneht, Carlo Genova, Erika Rijavec, Federica Biello, Simone Mennella, Maria Giovanna Dal Bello, Giuseppe Cittadini, Paolo Bruzzi, Roberta Piva, Valentina Ceriani, Gianmario Sambuceti, Egesta Lopci, Silvia Morbelli and Francesco Grossi
Journal of Nuclear Medicine December 2019, jnumed.119.233056; DOI: https://doi.org/10.2967/jnumed.119.233056
Giovanni Rossi
1 Lung Cancer Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matteo Bauckneht
2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Genova
1 Lung Cancer Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Rijavec
3 Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federica Biello
1 Lung Cancer Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Mennella
4 Radiology Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Giovanna Dal Bello
1 Lung Cancer Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Cittadini
4 Radiology Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Bruzzi
5 Epidemiology Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberta Piva
2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Ceriani
2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianmario Sambuceti
2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Egesta Lopci
6 Nuclear Medicine Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Morbelli
2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Grossi
3 Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.119.233056
DOI 
https://doi.org/10.2967/jnumed.119.233056
PubMed 
31806768

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online December 5, 2019.

Article Versions

  • You are currently viewing a previous version of this article (December 5, 2019 - 10:37).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Giovanni Rossi1,
  2. Matteo Bauckneht2,
  3. Carlo Genova1,
  4. Erika Rijavec3,
  5. Federica Biello1,
  6. Simone Mennella4,
  7. Maria Giovanna Dal Bello1,
  8. Giuseppe Cittadini4,
  9. Paolo Bruzzi5,
  10. Roberta Piva2,
  11. Valentina Ceriani2,
  12. Gianmario Sambuceti2,
  13. Egesta Lopci6,
  14. Silvia Morbelli2 and
  15. Francesco Grossi3
  1. 1 Lung Cancer Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  2. 2 Nuclear Medicine Unit, IRCCS Policlinico San Martino, Genoa, Italy, Italy;
  3. 3 Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;
  4. 4 Radiology Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  5. 5 Epidemiology Unit, IRCCS Policlinico San Martino, Genoa, Italy;
  6. 6 Nuclear Medicine Unit, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy, Italy
  1. For correspondence or reprints contact: Silvia Morbelli, San Martino Hospital, Largo R. Benzi 10, Genoa 16132, Italy. E-mail: silviadaniela.morbelli@hsanmartino.it

Statistics from Altmetric.com

Cited By...

  • 40 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0
    E. Lopci, R. J. Hicks, A. Dimitrakopoulou-Strauss, L. Dercle, A. Iravani, R. D. Seban, C. Sachpekidis, O. Humbert, O. Gheysens, A. W. J. M. Glaudemans, W. Weber, R. L. Wahl, A. M. Scott, N. Pandit-Taskar, N. Aide
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 7
  • [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab
    Damijan Valentinuzzi, Martina Vrankar, Nina Boc, Valentina Ahac, Ziga Zupancic, Mojca Unk, Katja Skalic, Ivana Zagar, Andrej Studen, Urban Simoncic, Jens Eickhoff, Robert Jeraj
    Radiology and Oncology 2020 54 3
  • PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions
    Chukwuka Eze, Nina-Sophie Schmidt-Hegemann, Lino Morris Sawicki, Julian Kirchner, Olarn Roengvoraphoj, Lukas Käsmann, Lena M. Mittlmeier, Wolfgang G. Kunz, Amanda Tufman, Julien Dinkel, Jens Ricke, Claus Belka, Farkhad Manapov, Marcus Unterrainer
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 12
  • Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
    Matteo Bauckneht, Selene Capitanio, Maria Isabella Donegani, Elisa Zanardi, Alberto Miceli, Roberto Murialdo, Stefano Raffa, Laura Tomasello, Martina Vitti, Alessia Cavo, Fabio Catalano, Manlio Mencoboni, Marcello Ceppi, Cecilia Marini, Giuseppe Fornarini, Francesco Boccardo, Gianmario Sambuceti, Silvia Morbelli
    Cancers 2019 12 1
  • Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
    Egesta Lopci
    Journal of Clinical Medicine 2021 10 21
  • The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer
    Rodney J. Hicks
    Seminars in Nuclear Medicine 2022 52 6
  • ImmunoPET: harnessing antibodies for imaging immune cells
    Anna M. Wu, Neeta Pandit-Taskar
    Molecular Imaging and Biology 2022 24 2
  • NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
    Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Désirée Deandreis
    Cancers 2021 13 18
  • Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods
    Narjess Ayati, Sze Ting Lee, S. Rasoul Zakavi, Melissa Cheng, W.F. Eddie Lau, Sagun Parakh, Kunthi Pathmaraj, Andrew M. Scott
    Journal of Nuclear Medicine 2021 62 7
  • The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
    Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Donegani, Federica Biello, Silvia Chiola, Lodovica Zullo, Stefano Raffa, Francesco Lanfranchi, Giuseppe Cittadini, Cecilia Marini, Egesta Lopci, Gianmario Sambuceti, Francesco Grossi, Silvia Morbelli
    Cancers 2021 13 13

Article usage

Article usage: December 2019 to April 2025

AbstractFullPdf
Dec 2019424041
Jan 2020144029
Feb 2020108015
Mar 2020118018
Apr 2020144011
May 202055011
Jun 202077037
Jul 20208881878
Aug 20203121228
Sep 20202041630
Oct 2020128614
Nov 2020110411
Dec 2020101413
Jan 20215410753
Feb 2021436656
Mar 2021287565
Apr 2021398262
May 2021318561
Jun 2021255659
Jul 2021205657
Aug 2021223587
Sep 2021212730
Oct 2021134048
Nov 2021194739
Dec 2021163837
Jan 2022203214
Feb 2022142112
Mar 2022183423
Apr 2022154739
May 2022203924
Jun 202252115
Jul 2022163614
Aug 2022103315
Sep 2022162412
Oct 202292219
Nov 20226218
Dec 202283215
Jan 2023234918
Feb 2023103516
Mar 2023323812
Apr 202381721
May 202382113
Jun 202383117
Jul 202321818
Aug 202391116
Sep 202332610
Oct 2023112213
Nov 2023882210
Dec 202343318
Jan 2024404111
Feb 202419108
Mar 202481918
Apr 20241411720
May 2024154415
Jun 2024141914
Jul 2024163223
Aug 20245218
Sep 20248229
Oct 202484419
Nov 2024121915
Dec 202473723
Jan 202512715
Feb 2025109321
Mar 202565832
Apr 2025113932
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (6)
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab
Giovanni Rossi, Matteo Bauckneht, Carlo Genova, Erika Rijavec, Federica Biello, Simone Mennella, Maria Giovanna Dal Bello, Giuseppe Cittadini, Paolo Bruzzi, Roberta Piva, Valentina Ceriani, Gianmario Sambuceti, Egesta Lopci, Silvia Morbelli, Francesco Grossi
Journal of Nuclear Medicine Dec 2019, jnumed.119.233056; DOI: 10.2967/jnumed.119.233056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab
Giovanni Rossi, Matteo Bauckneht, Carlo Genova, Erika Rijavec, Federica Biello, Simone Mennella, Maria Giovanna Dal Bello, Giuseppe Cittadini, Paolo Bruzzi, Roberta Piva, Valentina Ceriani, Gianmario Sambuceti, Egesta Lopci, Silvia Morbelli, Francesco Grossi
Journal of Nuclear Medicine Dec 2019, jnumed.119.233056; DOI: 10.2967/jnumed.119.233056
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Predictive value of 3'-deoxy-3'-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer
  • Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer
Show more Clinical Investigations (Human)

Clinical (Oncology: Lung)

  • First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
  • Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Show more Clinical (Oncology: Lung)

Similar Articles

Keywords

  • Oncology: Lung
  • PET/CT
  • Other
  • computed tomography
  • NSCLC
  • positron emission tomography
  • checkpoint inhibitors
SNMMI

© 2025 SNMMI

Powered by HighWire